Diagnostics

How CRISPR and Point-of-Care Platforms Are Reshaping the Infectious Disease Diagnostics Testing Market in 2026 

24LifeScience Market Intelligence

Clinicians no longer wait days for culture results when a patient arrives with fever, respiratory distress, or unexplained sepsis. Molecular tools now deliver answers in under an hour in many settings, and the pace continues to quicken.  

  • In November 2026 the FDA finalized streamlined guidance for validating in vitro diagnostics aimed at emerging pathogens under Section 564 emergency declarations.  

  • The document reduced the required analytical studies and clarified pathways for pre-EUA and EUA submissions, giving manufacturers clearer rules for bringing tests online during outbreaks. 

WHO’s Essential Package for Bacterial and Fungal Diagnostics 

  • The World Health Organization released its Essential Package of Diagnostic Tests for bacterial and fungal infections and antimicrobial resistance.  

  • The catalogue maps rapid, microscopy, culture, serological, and molecular methods to every tier of the health system, from primary care clinics to tertiary hospitals.  

  • It specifies specimen types and test purposes at each level so ministries of health can prioritize equipment and training where gaps remain largest.  

  • A companion landscape analysis of commercial and pipeline diagnostics for WHO bacterial priority pathogens highlighted persistent shortfalls in low-resource laboratories, especially for phenotypic susceptibility and genotypic resistance markers. 

CRISPR Platforms Moving From Bench to Bedside 

CRISPR-based assays are no longer confined to research papers. Platforms that combine isothermal amplification with Cas enzymes now detect bacterial species and key resistance genes with only a heat block and a simple reader. One such system, evaluated across more than two thousand reactions, identified nine Gram-negative pathogens and four major resistance genes at high accuracy without cold-chain reagents.  

In urinary tract infection workups the same approach achieved strong agreement with conventional methods while cutting time dramatically. Parallel work on amplification-free CRISPR panels aims to return respiratory results in roughly ten minutes, targeting the most common viruses that fill urgent-care waiting rooms. 

Tongue Swabs and Alternative Specimens for Tuberculosis 

Tuberculosis testing has long depended on sputum, a specimen many patients cannot produce easily. Engineers at Northwestern University adapted an existing rapid PCR system to accept tongue swabs as well as sputum. Results appear in twenty minutes and match the sensitivity of established molecular tests on true-negative samples while performing well on true positives.  

Because tongue swabs require minimal training and can be collected almost anywhere, the method opens testing to remote clinics and community outreach teams that previously sent samples to distant laboratories. 

Mobile Vans and Same-Visit Hepatitis C Diagnosis 

A San Francisco mobile van that already offered free hepatitis C screening added point-of-care RNA testing. Screening volume roughly doubled and identification of people with active infection rose more than twofold.  

Patients who once needed multiple visits for antibody screening, laboratory confirmation, and treatment initiation could often begin therapy on the third encounter. The experience illustrates how placing molecular capability directly in outreach settings converts testing volume into earlier treatment starts. 

You Can Go Through Our Latest Updated Insights Here: https://www.24lifesciences.com/infectious-disease-diagnostics-testing-market-9498 

Syndromic Panels in Everyday Respiratory and Gastrointestinal Care 

Multiplex panels that interrogate a single specimen for dozens of bacteria, viruses, and parasites continue to expand. Updated gastrointestinal panels received FDA clearance with redesigned norovirus assays and improved Campylobacter detection, returning results in about one hour from stool.  

Respiratory panels covering thirteen or more targets have gained CE marking under the European In Vitro Diagnostic Regulation, allowing laboratories and clinics to distinguish influenza, RSV, SARS-CoV-2, Bordetella, and atypical bacteria from one nasopharyngeal swab. These panels reduce sequential testing and support faster decisions on isolation and therapy. 

Metagenomic Sequencing for the Cases Culture Misses 

  • When standard panels return negative results yet the patient remains critically ill, metagenomic sequencing of respiratory specimens has identified additional pathogens in roughly one-quarter to one-third of cases in UK hospital networks.  

  • Influenza C, rare zoonotic viruses, and organisms never included on routine panels have been recovered within hours rather than days.  

  • The approach is still resource-intensive, yet its ability to answer the question “what is present that we did not expect?” is changing management in intensive-care and immunocompromised populations. 

Linking Diagnostics to Antimicrobial Stewardship on the Ground 

Rapid identification of resistance genes at the point of care directly influences antibiotic choice. CRISPR and multiplex molecular systems that report both organism and resistance markers allow clinicians to narrow therapy before phenotypic susceptibility results arrive. In settings where culture capacity is limited, these tools help preserve the effectiveness of remaining antibiotics by reducing empiric broad-spectrum use. 

The technologies described above are already operating in clinics, mobile units, and hospital laboratories. Their common thread is the progressive removal of barriers between sample collection and actionable result, whether that barrier is distance, time, specimen type, or the need for specialized infrastructure.